Clooper is a property management platform. The company argues that 86% of private landlords in the UK manage their properties themselves, with many finding it time-consuming and stressful. Clooper seeks to solve this problem with a property management platform that connects landlords, tenants, trade services, and homeowners to facilitate easy transactions between them. It aims to be a significant contender in the £11 billion property management platform. The company points out that Paul Rothwell of Empire, a large residential landlord in England, has pledged £200,000 of investment to the company. Clooper aims to make move-ins quicker, repairs faster, and payments easier in the wake of Covid-19 which is fuelling the adoption of online services in the UK. The company will use the investment to hire key recruits, operationalise mobile apps, boost marketing, and enhance sales and operations.
days to go:
Expired
investment:
£409,847
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.
days to go:
Expired
investment:
£691,497
Molecular Warehouse are trying to create a world where most diseases are prevented by giving people the chance to monitor and manage their helath where ever and whenever. Molecular Warehouse have developed a platform that allows anyone to test themselves at any time.
days to go:
Expired
investment:
£737,480
Lupe Technology (LT) aims to solve the frustrations that consumers were having with cordless vacuum cleaners. Its product, Lupe Pure Cordless Vacuum Cleaner, consists of the company's patented Suction Intensifier (SI) technology that can pick up dust more efficiently than conventional vacuum cleaners. Forbes calls the Pure Cordless 'The Rolls Royce of vacuum cleaners.' In 2019, LT completed the biggest ever crowdfunded vacuum cleaner campaign. In 2020, LT secured its first trade orders and completed a £560,000 Kickstarter campaign in 5 weeks. The company recorded profits of £100,000+ in November 2020 and achieved a positive Earnings Before Interest and Taxes (EBIT) position. LT will use 19% of the investment received towards marketing, 55% in stock, and 26% on overhead costs including payroll.
days to go:
Expired
investment:
£556,126
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year.
days to go:
Expired
investment:
£251,600
Sorbet is a proptech business which automates the processes of renting a house, aiming to streamline reporting, minimise the burden of administration and improve communication between agents, landlords, contractors and tenants.
days to go:
Expired
investment:
£239,341
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
An innovation event that displays the greatest in medical healthcare technologies within exhibitions, conferences and workshops. GIANT Health has over 2000 delegates registered, with 235 speakers and 33 exhibitors whilst being sponsored by 8 global companies. Current revenue streams consist of event ticket sales, partnership packages, stage demos, etc. Events are held across Europe, with international expansion in the next phase.
days to go:
Expired
investment:
£62,770
Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.
days to go:
Expired
investment:
£1,310,090
